Targeted Therapy Breast Cancer Treatment: How It Works, Results and What to Expect

Targeted therapy breast cancer treatment uses medicines that block or interfere with specific proteins or pathways helping cancer cells grow. It is chosen according to the tumor’s biomarker test results, cancer stage, prior treatments, and a person’s overall health.

Overview: how targeted therapy for breast cancer works

Targeted therapy breast cancer treatment uses medicines designed to act on particular features of cancer cells, such as a growth-promoting protein, an internal signaling pathway, or a weakness in how cells repair damaged DNA. Unlike chemotherapy, which affects rapidly dividing cells more broadly, targeted medicines are selected after laboratory testing identifies a relevant target. They may be given alone or combined with surgery, radiotherapy, chemotherapy, hormone therapy, or immunotherapy.

The best-known example is treatment for HER2-positive breast cancer. HER2 is a protein that can promote cancer cell growth when present in high amounts. Medicines may block HER2 signals, deliver chemotherapy directly to HER2-positive cells, or help the immune system recognize these cells. Other targeted approaches can act on pathways such as CDK4/6, PI3K, AKT, mTOR, PARP, or the antibody-drug conjugate targets identified in certain breast cancers.

Targeted therapy may be used before surgery to shrink a tumor, after surgery to lower the risk of recurrence, or for locally advanced or metastatic disease to control cancer and maintain quality of life. The treatment plan is individualized and is reviewed over time as test results, side effects, and the cancer’s response become clearer.

Who may be a candidate for targeted therapy?

Candidacy depends first on the cancer’s biology. A biopsy or surgical specimen is tested for estrogen and progesterone receptors and HER2 status. In some situations, doctors also test the tumor tissue or blood for gene changes that may guide treatment, such as PIK3CA, ESR1, BRCA1, BRCA2, or other relevant alterations. Not every breast cancer has a target for an available medicine.

HER2-targeted medicines are used when testing confirms HER2-positive disease. People with hormone receptor-positive, HER2-negative advanced breast cancer may be offered targeted medicines alongside endocrine therapy. PARP inhibitors may be considered for some people with HER2-negative breast cancer and inherited BRCA mutations. The exact option depends on disease stage, treatments already received, menopausal status, organ function, and personal priorities.

A multidisciplinary team typically reviews pathology, imaging, genetic information, and treatment goals. This helps distinguish a treatment that is likely to provide meaningful benefit from one that is unlikely to help. Understanding the breast cancer subtype is an essential starting point when planning breast cancer care.

What happens during targeted therapy treatment?

Before treatment starts, the oncology team confirms the target and discusses the intended purpose of therapy. Baseline blood tests are common. Depending on the medicine, additional checks may include heart function testing, liver and kidney tests, blood sugar monitoring, eye assessment, or genetic counseling and testing. The team also reviews other medicines, supplements, allergies, pregnancy plans, and medical conditions.

Some targeted medicines are tablets or capsules taken at home on a regular schedule. Others are given through a vein in an outpatient infusion unit, often every few weeks. An infusion visit may include vital-sign checks, a review of symptoms, blood tests, and time for the medication to be administered and observed. The schedule differs substantially between medicines.

During treatment, scans, physical examinations, and laboratory tests help assess whether the cancer is responding and whether treatment remains safe. If side effects occur, the clinician may recommend supportive medicines, a temporary pause, dose adjustment, or a change in treatment. People should not stop or alter a prescribed targeted medicine without speaking with their cancer team.

For people considering care pathways that include systemic treatment, breast cancer treatment planning can coordinate medicines with surgery and radiotherapy when appropriate.

Benefits, risks and recovery timeline

The main benefit of targeted therapy is precision: it can interfere with a known driver of a person’s cancer. In early breast cancer, it may reduce the chance of cancer returning. In advanced breast cancer, it can slow growth, shrink tumors in some people, relieve cancer-related symptoms, and extend the period of disease control. Benefits cannot be predicted from a target alone, and treatment response is monitored closely.

Targeted therapy is not automatically easier than chemotherapy. Side effects depend on the specific medicine and may include fatigue, diarrhea, nausea, skin changes, mouth sores, low blood counts, high blood pressure, liver test changes, increased blood sugar, or a higher infection risk. Some HER2-targeted treatments can affect heart function, which is why periodic heart monitoring may be needed. Serious side effects are less common but require prompt medical review.

There is usually no surgical-style recovery period because most targeted treatments are outpatient therapies. After an infusion, many people return to usual light activities the same day or the next day, depending on how they feel. With oral medicines, adjustment may take several weeks while the team identifies and manages side effects. Rest, regular fluids, balanced meals, gentle activity when possible, and scheduled monitoring can support day-to-day wellbeing.

Contact the oncology team urgently for fever, chills, trouble breathing, chest pain, severe or persistent diarrhea or vomiting, sudden swelling, a widespread rash, unusual bleeding, jaundice, or symptoms that feel severe or rapidly worse.

What is the success rate of targeted therapy for breast cancer?

There is no single success rate for targeted therapy in breast cancer. Outcomes vary according to the molecular subtype, whether cancer is early-stage or metastatic, the targeted medicine used, whether it is combined with other treatments, and how the individual cancer responds. A meaningful response may mean lowering recurrence risk after surgery, shrinking cancer before surgery, or controlling metastatic cancer for a period of time.

HER2-targeted therapy has substantially changed outcomes for many people with HER2-positive breast cancer, particularly when integrated with modern surgery, chemotherapy, endocrine therapy when indicated, and radiotherapy. However, the benefit for one person cannot be calculated from general figures alone. The oncology team can explain expected benefits in the context of pathology findings and the recommended treatment plan.

For metastatic breast cancer, doctors often discuss response, progression-free survival, and overall disease control rather than a cure rate. Regular imaging and symptom review show whether treatment is working, and a different option may be recommended if the cancer progresses or side effects become unacceptable.

Is targeted therapy hard on the body?

Targeted therapy can be physically demanding, but its effects are different from those of standard chemotherapy and vary greatly between medicines. Because these treatments act on a particular pathway, they may spare some healthy cells. However, the targeted pathway can also be important in normal tissues, which is why side effects still occur.

Many people can continue aspects of work, family life, and gentle exercise during therapy, especially when symptoms are recognized early and managed well. Others need more support, time away from usual activities, or changes to their regimen. Treatment burden can also include frequent appointments, tests, and the emotional uncertainty that may accompany cancer care.

Patients can help by keeping a record of symptoms, taking medicines exactly as directed, attending monitoring appointments, and asking early about problems such as diarrhea, fatigue, skin reactions, or sleep difficulties. Open communication enables the care team to tailor supportive care and protect safety without overlooking the value of treatment.

What is the success rate of targeted therapy for cancer?

Across all cancers, targeted therapy does not have one universal success rate. A targeted medicine works only when the cancer has the feature it is designed to treat and when that cancer remains sensitive to the medicine. Even within the same cancer type, responses can differ because tumors may have different genetic changes and can evolve over time.

Some targeted therapies produce major and durable responses, while others provide more modest or temporary disease control. In early cancers, benefit is often measured by a reduced risk of recurrence. In advanced cancers, it is commonly measured by tumor response, symptom improvement, or the length of time before the cancer grows again.

Biomarker testing and ongoing assessment are therefore central to treatment decisions. If a targeted medicine stops working, the oncologist may recommend another targeted option, a different systemic treatment, a clinical trial where suitable, or care focused on symptom control and quality of life.

How long can you stay on targeted therapy and when to seek medical care

The duration of targeted therapy depends on its purpose and the specific medicine. After surgery for early breast cancer, some HER2-targeted treatment plans have a planned, time-limited course. Before surgery, treatment may be given for a defined number of cycles. For metastatic breast cancer, targeted therapy is often continued as long as it is controlling the cancer and side effects remain manageable.

Some people need a treatment pause or a change in medicines due to side effects, progression, or changing health needs. Continuing therapy is a shared decision that considers scan results, blood tests, symptoms, daily functioning, and the person’s goals. There is no standard duration that applies to everyone.

Medical care should be sought promptly for severe symptoms or a sudden decline in wellbeing during treatment. The oncology team should also be contacted for new lumps, persistent bone pain, unexplained weight loss, lasting cough or breathlessness, neurological symptoms, or any symptom that raises concern. In an emergency, such as severe breathing difficulty, chest pain, fainting, or signs of a serious allergic reaction, emergency services should be contacted immediately.

Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals diagnose and treat breast cancer for international patients, coordinating systemic therapies with supportive care and follow-up.

Frequently asked questions

Is targeted therapy the same as chemotherapy for breast cancer?

No. Chemotherapy affects rapidly dividing cells more broadly, while targeted therapy is designed to act on a particular protein, pathway, or genetic change in cancer cells. The two treatments may be used together because they work in different ways.

Will everyone with breast cancer receive targeted therapy?

No. Targeted therapy is used only when testing identifies a suitable target and the expected benefits outweigh the risks. Treatment choices also depend on the cancer stage, previous therapy, overall health, and personal treatment goals.

How is HER2 status tested?

HER2 status is usually tested on tissue from a breast biopsy or surgery. Laboratory tests examine whether the tumor has extra HER2 protein or extra copies of the HER2 gene, and an additional test may be used if the first result is unclear.

Can targeted therapy be used before breast cancer surgery?

Yes. For some cancers, especially certain HER2-positive tumors, targeted medicines may be given before surgery with other systemic treatments. This approach can shrink the tumor and helps the team assess how the cancer responds.

Can targeted therapy cause hair loss?

Some targeted medicines can contribute to hair thinning or hair loss, but this is not a side effect of every targeted treatment. Hair loss is more commonly associated with chemotherapy, including when chemotherapy is combined with targeted therapy. The cancer team can explain what is expected with a specific regimen.

Can targeted therapy stop working?

Yes. Cancer cells can sometimes develop resistance, allowing the cancer to grow despite treatment. Regular monitoring helps detect this, and the oncology team may recommend another targeted medicine or a different treatment approach if needed.

References

• National Cancer Institute
• American Cancer Society
• European Society for Medical Oncology
• American Society of Clinical Oncology
• Breast Cancer Now

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.